Sunday, February 14, 2016

Glaxo's diabetes drug Avandia restricted in US, off market in Europe

The Food and Drug Administration announced Thursday that it has decided to "significantly restrict" the use of rosiglitazone, the GlaxoSmithKline diabetes drug sold under the brand name Avandia. The FDA said Avandia would be available only to "patients who cannot control their diabetes on other medications" because of data suggesting that the drug increases the risk of heart attacks, heart failure, stroke and other cardiovascular events.

Glaxo’s diabetes drug Avandia restricted in US, off market in Europe

0 comments

The Food and Drug Administration announced Thursday that it has decided to “significantly restrict” the use of rosiglitazone, the GlaxoSmithKline diabetes drug sold under the brand name Avandia.

The FDA said Avandia would be available only to “patients who cannot control their diabetes on other medications” because of data suggesting that the drug increases the risk of heart attacks, heart failure, stroke and other cardiovascular events.

While a blow to Glaxo, which has major operations and thousands of employees in the Philadelphia region, the European Medicines Agency took the more drastic step of ordering the drug and other two other medications that contain rosiglitazone (Avandamet and Avaglim) off the market in Europe.

“These medications will stop being available in Europe within the next few months,” the European drug agency said. “Patients who are currently taking these medicines should make an appointment with their doctor to discuss suitable alternative treatments.”

The European agency said its “suspension” of Avandia and the other medications would stay in place unless Glaxo “can provide convincing data to identify a group of patients in whom the benefits of the medicines outweigh their risks.”

In a statement, Glaxo acknowledged the regulatory actions in the US and Europe and added, “the company continues to believe that Avandia is an important treatment for patients with type 2 diabetes and is now working with the FDA and EMA to implement the required actions.”

See full story here.

To check out more Check Up items go to www.philly.com/checkup.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Check Up is a blog for savvy health consumers, covering the latest developments, discoveries, and debates from the Philadelphia area and beyond.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Charlotte Sutton Health and Science Editor, Philadelphia Inquirer
Tom Avril Inquirer Staff Writer, heart health and general science
Stacey Burling Inquirer Staff Writer, neuroscience and aging
Marie McCullough Inquirer Staff Writer, cancer and women's health
Don Sapatkin Inquirer Staff Writer, public health
David Becker, M.D. Board certified cardiologist, Chestnut Hill Temple Cardiology
Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter